OnKure (OKUR) Director Isaac Manke Receives Repriced Options

What Happened

• Isaac Manke, a director of OnKure Therapeutics (OKUR), is reported to have received a repriced option award covering 300,000 derivative shares on August 7, 2026. The filing shows the acquisition of 300,000 derivative shares at $0.00 (reflecting an amendment to option terms rather than a cash purchase).
• The Form 4 also reports a same-day disposition to the issuer of 15,300 derivative shares and an acquisition of 15,300 derivative shares on Aug 7, 2026 — recorded in the filing as related transactions tied to the option repricing. No cash sales or open-market purchases are reported.

Key Details

• Transaction date: August 7, 2026; Form 4 filed August 11, 2026 (filed after the transaction date; Form 4s are generally due within 2 business days).
• Repricing specifics: Under a one-time Option Repricing effective Aug 7, 2026, options with original exercise prices ≥ $10.00 were amended to an exercise price of $4.14 per share (the closing price on Aug 7, 2026). There was no change to vesting schedules, expiration dates, or the number of shares.
• Vesting notes: Footnotes state differing vesting schedules for affected options — e.g., one option vests 1/4 on Feb 24, 2027 then 1/48th monthly thereafter (F1); another vested 1/36th on Nov 4, 2024 and vests 1/36th monthly thereafter (F2).
• Retention premium: If a holder exercises a repriced option before the end of the "Retention Period" (Aug 7, 2026 through the earlier of Feb 7, 2028 or a change in control), they must pay a premium exercise price equal to the original exercise price (i.e., the repriced option is subject to a potential premium if exercised early) (F4).
• Shares owned after the transactions: not specified in the excerpted filing.

Context

• These are derivative transactions (option repricings/amendments), not open-market purchases or sales. The reported $0.00 acquisition reflects the amendment of option terms rather than new cash consideration.
• The paired disposition and acquisition of 15,300 derivative shares on the same date appear as administrative adjustments recorded in the filing and are presented as part of the overall repricing event.
• Repricings are management decisions to reduce exercise prices on outstanding options; they do not by themselves indicate that an insider bought or sold actual shares.